论文部分内容阅读
目的研究分析早期采用重组人脑利钠肽(新活素)治疗对急性重症左心衰竭(SALHF)患者血浆N末端钠尿肽前体(NT-proBNP)及肌酐水平的影响。方法选取2012年4月至2013年4月收治的SALHF患者86例,随机分为观察组(43例)和对照组(43例)。对照组给予常规型抗心衰治疗,观察组在对照组基础上早期采用新活素治疗,对比两组患者血浆NT-proBNP、肌酐水平及心功能情况。结果两组治疗前NT-proBNP、肌酐水平相当(P均>0.05);观察组治疗后血浆NT-proBNP[(12 927.88±8 717.63)pg/ml]和肌酐[(112.38±9.07)μmol/L]水平均显著低于治疗前[(19 214.32±11 728.55)pg/ml、(135.77±15.34)μmol/L]及对照组治疗后[(19 223.79±9 024.54)pg/ml、(133.12±13.18)μmol/L],差异有统计学意义(P均<0.01)。观察组患者总有效率(93.02%)显著高于对照组(58.14%,P<0.01)。结论对SALHF患者早期采用新活素治疗,可有效改善血浆NT-proBNP及肌酐水平,提高心、肾功能及治疗效果。
Objective To investigate the effect of early treatment with recombinant human brain natriuretic peptide (NTN) on plasma NT-proBNP and creatinine in patients with acute severe left heart failure (SALHF). Methods A total of 86 patients with SALHF admitted from April 2012 to April 2013 were randomly divided into observation group (43 cases) and control group (43 cases). The control group was given conventional anti-heart failure treatment. The observation group was treated with nesiritide on the basis of the control group. The levels of plasma NT-proBNP, creatinine and cardiac function in the two groups were compared. Results The levels of NT-proBNP and creatinine in both groups before treatment were comparable (P> 0.05). The levels of plasma NT-proBNP [(12 927.88 ± 8.77.63) pg / ml] and creatinine [(112.38 ± 9.07) μmol / L ] Were significantly lower than before treatment [(19 214.32 ± 11 728.55) pg / ml, (135.77 ± 15.34) μmol / L] and control group after treatment [(19 223.79 ± 9 024.54) pg / ml, (133.12 ± 13.18 ) μmol / L], the difference was statistically significant (P <0.01). The total effective rate in the observation group (93.02%) was significantly higher than that in the control group (58.14%, P <0.01). Conclusions The use of neomycin for early treatment of SALHF patients can effectively improve the level of plasma NT-proBNP and creatinine, and improve heart and renal function and therapeutic effect.